PHARMA MICROGRAVITY · OPERATOR PROFILE · DATA AS OF 2026-07-28

Varda Space Industries

Active Pharma Microgravity Private HQ: El Segundo, California

Microgravity-enabled life-sciences company operating W-Series free-flying orbital platforms that process pharmaceutical active ingredients and materials in orbit and return product to Earth. Also serves as a hypersonic testbed for reentry and orbital flight testing.

39.5

ARI Composite

Very High Risk

#27 of 33

Peer Rank

Infrastructure cohort

—

Total Launches

No flights tracked

—

Estimated valuation

Not disclosed

FINANCIAL HEALTH

39.5

ARI composite · Very High Risk

Peer rank#27 of 33

Peer groupInfrastructure

Data coverage72%

Tracked gov contracts$18.2M across 3 awards

Full finance profile →

CAPITAL & CREDIT PROFILE

Government capital

$18.2M lifetime tracked obligations across 3 awards — top agency Department of Defense ($18.2M) (strict id-matched; unattributed award rows are excluded). Explore grants →
Source: USAspending.gov award obligations matched to this company. Obligations, not recognized revenue.

SECTOR POSITION

Primary sectorPharma Microgravity

Rank within sector#27 of 33

Tracked peers33

RECENT COVERAGE

Date	Source	Headline
Jul 23, 2026	SpaceNews	Will Bruey on rethinking the role of pharmaceuticals in low Earth orbit
Jun 24, 2026	Payload Space	SpaceX Starfall Demo Provides Validation for Reentry Startups
Jun 23, 2026	NASASpaceFlight	Launch Preview: Pegasus XL to launch amongst Falcon 9 and Chinese missions
May 21, 2026	SpaceNews	Sixth Varda mission successfully returns
May 13, 2026	Ars Technica — Space	Could this be the moment that drug manufacturing takes off in orbit?

REGISTRY DATA

Legal nameVarda Space Industries, Inc.

OwnershipPrivate

HeadquartersEl Segundo, California

CountryUS

AliasesVarda, Varda Space, Varda Space Industries

Key programsW-Series (W-1, W-2, W-3, W-4, W-5, W-6)

Gov customersDoD, Air Force, NASA

IPO statusPrivate

Source: space_company_registry.json · Operator homepage → · Corporate homepage (El Segundo, CA HQ; 2026 copyright) documents Varda's microgravity-enabled life-sciences platform and W-Series reentry missions through W-6, establishing operator status in the phar

METHODOLOGY

Launch history and subsystem outcomes aggregate from AstraVeris's launch_events table with Wilson 95% lower bounds on success rates. ARI scores come from the 11-factor composite (/finance/methodology/). Constellation counts derive from the live CelesTrak/GCAT object catalog. Gov contracts from USAspending.gov awards; private deals from deduplicated pipeline deal extraction. Absence of a row means "not tracked" — we never fabricate. See /methodology/ for the full data model and /data-licensing/ for licensing terms.

Not investment advice. For insurance underwriting, verify against primary-source filings and operator investigation reports.